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S-adenosylmethionine arises as a central molecule in the preservation of liver homeostasis as a chronic
hepatic deficiency results in spontaneous development of steatohepatitis and hepatocellular carcinoma.
In the present work, we have attempted a comprehensive analysis of proteins associated with
hepatocarcinogenesis in MAT1A knock out mice using a combination of two-dimensional electrophoresis
and mass spectrometry, to then apply the resulting information to identify hallmarks of human HCC.
Our results suggest the existence of individual-specific factors that might condition the development
of preneoplastic lesions. Proteomic analysis allowed the identification of 151 differential proteins in
MAT1A-/- mice tumors. Among all differential proteins, 27 changed in at least 50% of the analyzed
tumors, and some of these alterations were already detected months before the development of HCC
in the KO liver. The expression level of genes coding for 13 of these proteins was markedly decreased
in human HCC. Interestingly, seven of these genes were also found to be down-regulated in a pretumoral
condition such as cirrhosis, while depletion of only one marker was assessed in less severe liver
disorders.
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Introduction
Since its discovery in 1953 by Cantoni,1,2 an increasing
number of studies provide evidences supporting the central
function of S-adenosylmethionine (AdoMet) in cell biology.
Along with ATP, AdoMet is one of the metabolites most
frequently used in intermediary metabolism. It is the main
alkylating agent in living cells participating in the methylation
of nucleic acids, proteins, phospholipids, hormones, xeno-
biotics, and other molecules through the transference of its
methyl group to the acceptors in reactions catalyzed by
methyltransferases. Additionally, AdoMet is involved in the
biosynthesis of different metabolites such us polyamines,
biotin, and, in the liver, is an intermediary metabolite in the
synthesis of cysteine and glutathione2-4 Methionine adenos-
yltransferase (MAT) catalyzes the only known AdoMet biosyn-
thetic reaction using methionine and ATP as substrates.1,5 In
mammalian tissues two distinct genes, MAT1A and MAT2A,6-9
encode three different MAT isoforms.9-12 MAT2A encodes a
396-amino acid R2 catalytic subunit that forms the tetrameric
MATII.5,13 MAT1A encodes a 395-amino acid R1 subunit that
organizes into dimers, MATIII, and tetramers, MATI.8,10,14-16 The
three MAT species catalyze the same reaction but their tissue
distribution, kinetics, and regulation are different.17 The expres-
sion of MAT1A is restricted to liver and pancreas,18 while
MAT2A is mainly expressed in extrahepatic tissues and also
predominates in the fetal liver where is progressively replaced
by MAT1A during development.19,20 Hepatic MAT activity and
expression are impaired in pathological conditions such as
human cirrhosis and in a variety of experimental models
including liver injury induced by ethanol, CCl4, galactosamine,
bacterial lipopolysaccharide, and hypoxia.5,13,21 The importance
of this alteration in AdoMet synthesis in the pathogenesis of
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liver disorders is supported by the finding that exogenous
AdoMet administration protects from the hepatotoxic effects
of these agents5,13 and increases survival in patients with
alcoholic liver cirrhosis.22 In adult liver, increased expression
of MAT2A and MAT1A silencing is associated with rapid growth
or de-differentiation of the liver, as during liver regeneration
induced by partial hepatectomy23,24 and in hepatocarcino-
genesis.25-27 The cellular content of AdoMet seems to be related
to the differentiation status of the hepatocyte.17 In this regard,
quiescent hepatocytes display higher AdoMet content that
proliferating hepatocytes17 resulting from a switch in gene
expression from MAT1A to MAT2A.23-27 Previous work shows
that AdoMet helps to turn off the hepatocyte responses to
growth factors, and that without this protection, the uncon-
trolled progression of cancer takes place.24 Thus, KO mice
deficient in AdoMet synthesis (MAT1A-/-) spontaneously de-
velop oxidative stress, non alcoholic steatohepatitis (NASH),
and hepatocellular carcinoma (HCC) by 8 and 18 months of
age respectively.28-30
Primary liver cancer is the fifth most frequent neoplasm and
the third most common cause of cancer related death with
more than 500 000 new cases diagnosed yearly.31 Hepatocellular
carcinoma (HCC) is a major health problem in Asia and Africa
with an incidence steadily increasing in western countries.31
Major causes of HCC are currently known, including infection
with hepatitis B (HBV) and C (HCV) viruses, ingestion of
aflatoxin contaminated food and alcohol abuse.32 Other less
prevalent risk factors have also been described such as iron or
cooper deposition or nonalcoholic steatohepatitis (NASH).33
Although the identification of the main risk factors and the
routine screening of population at risk may lead to the early
diagnosis of HCC, the prognosis of these patients is poor mainly
due to the aggressiveness of the lesions at the time of diagnosis
and to the lack of effective therapies. Therefore, the improve-
ment of our knowledge about the molecular pathogenesis of
HCC and the identification of biomarkers leading to an early
diagnosis are of great interest and one of the priorities of
clinical hepatology. At present, only five biomarkers for HCC
are available for clinical use,34 from which only alpha fetopro-
tein partially fulfils the requirements of an ideal tumor marker.34
The recent technological advances in genomics and proteomics
greatly promoted the systematic analysis of global gene expres-
sion and protein abundance profiles of normal and diseased
tissue, providing new insights into the pathogenic mechanisms
of human diseases35-37as well as disease-associated targets.
In the present work, we have attempted a comprehensive
analysis of proteins associated with hepatocarcinogenesis in
MAT1A-/- mice using a combination of two-dimensional
electrophoresis (2-DE) and mass spectrometry to then apply
the resulting information to identify hallmarks of human HCC.
Our results provide evidences suggesting that stochastic alter-
ations associated with tumor growth as well as the selective
pressure imposed by individual-specific factors on preneoplas-
tic foci contribute to increase proteome heterogeneity between
tumor nodules. Among 151 differential proteins identified in
the mouse model, we found a cluster of 15 proteins that may
prove to be useful in the early diagnosis of human HCC.
Experimental Section
Materials. Electrophoresis reagents were from Bio-Rad,
trypsin was from Promega, urea was from USB. Ethanol and
trifluoroacetic acid were from Merck. All other reagents were
from Sigma. Animals were from our inbred colony and were
treated humanely, according to our institution’s guidelines. We
obtained liver samples from 5 groups of subjects (age range
40-80): (a) Control individuals (n ) 12); (b) patients with
alcoholic liver cirrhosis (n ) 5); (c) patients with viral liver
cirrhosis (n ) 10); (d) patients with primary HCC (n ) 10); (e)
peritumoral liver samples from patients with primary HCC
without liver cirrhosis (n ) 10). HCC patients were not receiving
any preoperative therapy such as chemotherapy, percutaneous
ethanol injection, or transcatheter arterial embolization. Con-
trol human liver tissue was obtained from patients in whom
a cholecystectomy was performed for the treatment of a
sympthomatic cholelithiasis and who consented to be submit-
ted to a liver biopsy during the surgical procedure. In the
control group, both the liver function tests and liver histology
were normal or showed minimal changes. Cirrhotic liver
samples were obtained at the time of transplantation, and
cancerous tissue during surgical resection. This study was
approved by the human research review committee of the
University of Navarra. Studies were conducted in compliance
with the ethical standards formulated at the Helsinki Declara-
tion of 1996 (revised in 2000).
Methods. Protein Separation by Two-Dimensional Elec-
trophoresis. Liver tumors were measured, resected and im-
mediately freeze clamped in liquid nitrogen. Samples were then
stored at -80 °C until use. Before proteomic analysis, sections
from formalin fixed tissue were stained with hematoxylin and
eosin and examined by two pathologists unaware of the
animals’ identity. In all cases, MAT1A-/- liver tumors are
composed of hepatocytes having round-to-oval nuclei and
prominent nucleoli, forming thickened trabecular cords lined
by endothelial cells. Tumor specimens were homogenized in
20 volumes of lysis buffer containing 7 M urea, 2 M thiourea,
4% (v/v) CHAPS, 1% (v/v) DTT and 0.5% Bio-Lyte 3-10
ampholytes. Homogenates were spinned down at 100 000  g
for 45 min at 15 °C. Protein concentration was measured in
the supernatant with the Bradford assay kit (BioRad), using
bovin serum albumin as standard protein. Protein separation
by two-dimensional electrophoresis (2DE) was performed as
described previously.30 Analytical gels (total protein amount was
150 íg) were stained with Sypro Ruby. Preparative gels (total
protein amount was 800 íg) were visualized with Coomassie
Safe Stain (Invitrogen). Gel scanning was performed with a
Molecular Imager FX and a densitometer GS800 (BioRad).
Images were processed with the PDQuest 7.1 analysis software.
To diminish the inherent variability associated with 2DE
analysis, the optical density of each spot was normalized using
the optical density calculated for all matched spots. All samples
were analyzed in triplicate. Quantitative differences were only
accepted when at least a 3-fold change was confirmed in all
three independent experiments. Spots differentially represented
were excised manually and gel specimens were processed with
a MassPrep station (Waters) as described elsewhere.30 In-gel
tryptic digestion was performed with 6 ng/íL trypsin in 50 mM
ammonium bicarbonate for 5 h at 37 °C. The resulting peptides
were extracted with 1% formic acid, 2% acetonitrile.
Protein Identification by Mass Spectrometry. Peptide mass
fingerprints (PMF) were obtained from the tryptic digests using
a MALDI-TOF GL-REF mass spectrometer from Waters. Briefly,
1.2 íL of the tryptic digest were mixed with an equal volume
of R-cyano-4-hydroxy-trans-cynnamic acid in 0.1% TFA in 50%
acetonitrile and spotted onto a MALDI-TOF target plate. The
system was calibrated daily with a tryptic digest of ADH. Data
Molecular Profiling of Hepatocellular Carcinoma research articles
Journal of Proteome Research ¥ Vol. 5, No. 4, 2006 945
processing was performed with Masslynx 4.0 (Waters) using
ACTH as internal lock-mass standard.
Microcapillary reversed phase LC was performed with a
CapLC (Waters) capillary system. Reversed-phase separation
of tryptic digests was performed with an Atlantis, C18, 3 ím, 75
ím  10 cm Nano Ease fused silica capillary column (Waters)
equilibrated in 5% acetonitrile, 0.2% formic acid. After injection
of 6 íL of sample, the column was washed during 5 min with
the same buffer and the peptides were eluted using a linear
gradient of 5-50% acetonitrile in 30 min at a constant flow
rate of 0.2 íL/min. The column was coupled online to a Q-TOF
Micro (Waters) using a PicoTip nanospray ionization source
(Waters). The heated capillary temperature was 80 °C and the
spray voltage was 1.8-2.2 kV. MS/MS data were collected in
an automated data-dependent mode. The three most intense
ions in each survey scan were sequentially fragmented by
collision induced dissociation (CID) using an isolation width
of 2.5 and a relative collision energy of 35%. Data processing
was performed with Masslynx 4.0.
Database searching was done with Proteinlynx Global Server
2.0 (Waters). Database used in this study were Swiss-Prot
(release 46.3) and Ensembl Mouse (release 29.33) containing
176 469 and 31 535 sequence entries, respectively. Data analysis
and protein clustering were done with GARBAN II (http://
garban.tecnun.es/garban2/index.php).38 This bioinformatic tool
is implemented with applications that allow gene and protein
classification according to Gene Ontology criteria.39
Protein identification was performed automatically but all
individual spectra were subsequently inspected manually to
ensure the certainty of the result. Protein identifications based
on PMF were only accepted when the Masslynx score was at
least 7 and the matched peptides represent at least 30% of the
proposed protein sequence. Protein identifications from
MS/MS data were only considered for score values above 7 and
when were based on the sequence of at least 3 independent
peptides.
RNA Isolation, RT-PCR and Real-Time PCR. Total RNA was
extracted using TRI reagent (Sigma). RNA was treated (2 íg)
with DNaseI (Invitrogen) prior to reverse transcription with
M-MLV Reverse Transcriptase (Invitrogen) in the presence of
RNaseOUT (Invitrogen). Primers were designed to amplify
specifically cDNA and all PCR products were sequenced to
confirm the specificity. Real-time PCR was performed with 1/20
of the PCR reaction using an iCycler (BioRad) and the iQ SYBR
Green Supermix (BioRad). The primers used are shown in Table
1. mRNA levels were normalized according to histone H3F3A
quantitation in the same sample. The primers used for histone
H3F3A amplification were as follows: 5′-aaagccgctcgcaagagt-
gcg-3′ and 5′-acttgcctcctgcaaagcac-3′. To monitor the specific-
ity, final PCR products were analyzed by melting curves and
electrophoresis. The amount of transcripts was calculated and
expressed as the relative difference to the control gene histone
H3F3A (2¢Ct, where ¢Ct represents the difference in threshold
cycles between the target and control genes), essentially as
described elsewhere.40 RNA from five control individuals and
milliQ water were used as positive and negative controls for
the real-time PCR analyses.
Statistical Analysis. Data are given as mean ( SD. For
changes in mRNA levels between controls and liver diseased
patients a global analysis including all experimental conditions
was performed using a Kruskall Wallis test. The test indicated
significant differences between groups. Paired analysis was then
performed with the Mann-Withney test considering the cor-
rection of Bonferoni. The threshold for significance was an
expected false discovery rate less than 0.05.
Results
Proteomic Analysis of HCC in MAT1A-/- Mouse. The
identification of proteins associated with HCC in MAT1A-/-
mice was performed by differential proteomics comparing 2-DE
patterns of normal and tumoral tissue from 18 month old WT
and KO mice respectively (Figure 1). Initially, five different WT
liver samples and KO tumors were analyzed in triplicate to
determine the degree of proteome variability in each group and
to ensure the reproducibility of the method. On the basis of
the results of the image analysis with PD Quest (BioRad), an
average of 800 to 1200 spots were visualized depending on the
amount of protein processed and the gel staining procedure.
Comparison of 2-DE profiles from normal liver revealed an
Table 1. Designed Primers Used in RT-PCR and Real Time PCR
ornithine aminotransferase 5′-tgtgtctgcagtctgtgtg-3′ 5′-agacacaccttccaagcatc-3′
malate dehydrogenase 5′-ggagcagctggtcaaattgc-3′ 5′-tccatgccttcccttcttgg-3′
antioxidant protein 2 5′-caactttgaggccaataccac-3′ 5′-tccttgctccaggcaagatg-3′
aldehyde dehydrogenase mit. 5′-gagcagcaacctcaagagag-3′ 5′-cgaggatcttcttaaactgag-3′
glycine N-methyltransferase 5′-gctggtggaagagggcttc-3′ 5′-cctttgcagtctggcaagtg-3′
sorbitol dehydrogenase 5′-atcttcttctgtgccacgcc-3′ 5′-gctcccattgctttggccac-3′
apolipoprotein E 5′-gttgctggtcacattcctgg-3′ 5′-taggccttcaactccttcatg-3′
serum albumin 5′-atgcctgctgacttgccttc-3′ 5′-ctgaggctcttccacaagag-3′
apolipoprotein A1 5′-gacagcggcagagactatg-3′ 5′-ccaccttctggcggtagag-3′
glutathione S-transferase P2 5′-agttccaggacggagacctc-3′ 5′-cagggtctcaaaaggcttcag-3′
methionine adenosyltransferase I 5′-agtcatccctgtgcgcatc-3′ 5′-ggtccaccttggtgtagtc-3′
carbonic anhidrase III 5′-tcctgaccactggcatgaac-3′ 5′-tgctcagagccatgatcatc-3′
protein disulfide isomerase 5′-tctccaaataccagctcgac-3′ 5′-caggatcttgcccttgaagc-3′
adenosylhomocysteinase 5′-gtccagctgcaacatcttctc-3′ 5′-cagtcgtggtctcctcagag-3′
heat shock cognate 71 kDa 5′-gatgaaggaaattgcagaagc-3′ 5′-caatagtgaggattgacacatc-3′
nonspecific lipid transfer prot. 5′-tggctcttgggtttgagaag-3′ 5′-catcttggaactgggaatacg-3′
phenylalanine 4-hydroxilase 5′-ggtgccacagtccatgagc-3′ 5′-ggcggtagttgtaggcaatg-3′
alcohol dehydrogenase 5′-gatgcctctgattggtctgg-3′ 5′-cttggatgtcacaaacagctc-3′
arginase 1 5′-caggattctcctgggtgac-3′ 5′-gatgtagagaccttctctg-3′
selenium binding protein 5′-cttcagcaactggcttgcatg-3′ 5′-gctgagctggatcatctgag-3′
glutamine synthase 5′-agcccaagtgtgtggaagag-3′ 5′-tgctggttgctcaccatgtc-3′
phosphoglucomutase 5′-aagaagatcctctgtgaagaac-3′ 5′-gaatgctgaagatgttggcag-3′
senescence marker protein 30 5′-tcaatgatgggaaggtggatc-3′ 5′-agggtcatagtcaaaggcatcc-3′
ornithine carbamoyltransferase 5′-ggaacaatatcctgcactcc-3′ 5′-ctgtaattaatacattgcctcc-3′
glutathione S-transferase mu1 5′-cctggaatacacagactcaag-3′ 5′-tcttctcctcttctgtctcc-3′
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intra-group variability values (defined as the ratio differential
spots/analyzed spots  100) lower than 1%, similar to those
measured in previous studies of MAT1A-/- livers under different
pathological conditions. However, variability increased signifi-
cantly after HCC development, as manifested by comparison
of tumor 2-DE maps (Figure 2). To investigate the origin of this
proteome heterogeneity, gel maps from 2 mm and 10 mm
neoplastic lesions from the same or different animals were
compared. As expected, the examination of tumors excised
from the same liver showed a positive correlation between
tumor size and variability (1.38 ( 0.34% and 3.4 ( 0.73% for 2
mm and 10 mm tumors respectively), in agreement with
previous hypothesis suggesting a stochastic accumulation of
proteomic changes in parallel with tumor growth. However,
the analysis of tumors from different mice showed variability
values 10-fold higher (7.8 ( 1.51% and 11 ( 1.79% for 2 mm
and 10 mm tumors respectively) than those in the WT group
(0.8 ( 0.08%) (Figure 2). These observations suggest that, in
addition to tumor growth, individual-specific factors might
contribute to proteome heterogeneity in HCC by imposing a
selective pressure on preneoplastic foci. To identify the dif-
ferential proteins associated with HCC in MAT1A-/- mice,
tumor extracts from 6 different animals were processed in
triplicate using preparative 2-DE (800 íg protein). Each gel
image was compared with WT maps to identify the differential
spots of individual tumors, and changes were only accepted
when at least 3-fold increase or decrease was confirmed in the
three independent experiments. Taking together all these
analysis, 227 differential spots were detected from which 151
proteins were successfully identified by mass spectrometry,
according to the criteria described in the methods section
(Table 1 supp. info). Since 2-DE analysis is likely restricted to
the most abundant proteins, alterations other than those
reported in this study might also participate in the development
of HCC in MAT1A-/- mice. We have found a linear correlation
between the Mr and pI calculated from the sequence of the
identified proteins and the experimental electrophoretic mobil-
ity of the corresponding spot, calculated from the 2DE gels
(Figure 3). This finding further validates the identity of the
analyzed spots. However, pI and Mr deviations from linearity
were observed, probably resulting from postraductional modi-
fications and abnormal protein processing as in the case of
aldehyde dehydrogenase class 2, albumin and glutathione
S-transferase Mu1. The identity of these protein species (Figure
3) was confirmed by de novo sequencing based on the results
from ESI-MS/MS analysis. According to previous genomic and
proteomic studies of HCC,34,41-46 among the 151 positive
identifications, most of the changes (61.3%) were down-
regulated proteins, suggesting the de-differentiation of hepa-
tocytes associated with the neoplastic transformation.45 Up-
and down-regulated proteins were classified with GARBAN II38
by the biological processes in which they are involved and by
Figure 1. Representative analytical 2D gels from WT liver and
MAT1A-/- liver tumor.
Figure 2. Proteome heterogeneity in liver tumors of MAT1A-/-
mice. Variability values (defined as the ratio differential spots/
analyzed spots  100) between the 2-DE profiles from normal
liver and tumors were analyzed. Gel maps from 2 and 10 mm
neoplastic lesions from the same or different animals were
compared. Tumor excised from the same liver (black) showed a
positive correlation between tumor size and variability. The
analysis of tumors from different mice (white) showed variability
values 10-fold higher than those found in the WT group.
Figure 3. Correlation between the theoretical Mr and pI and the
experimental relative mobility of differential proteins on 2DE.
Most of the analyzed proteins, showed a linear correlation
between the Mr (upper panel) and pI (lower panel) calculated
from the sequence of the identified proteins and experimental
electrophoretic mobility of the corresponding spot, calculated
from the 2-DE gels. Protein species with anomalous pI and/or
Mr are indicated.
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their subcellular location, according to the Gene Ontology
criteria39 (Figures 1 and 2 of the Supporting Information). Most
proteins differentially expressed were involved in response to
external stimulus, cellular organization and biogenesis, me-
tabolism, stress response, and transport (Figure 1 of the
Supporting Information and Table 1 of the Supporting Infor-
mation) and the subcellular components mainly altered were
mitochondria, cytoeskeleton, endoplasmic reticulum, and
nucleus (Figure 2 of the Supporting Information). About 50%
of the proteins differentially expressed were metabolic enzymes.
The high representation of metabolic enzymes among the
identified proteins might be associated with their relative
abundance in the liver, according with the biological activity
of this organ. Most of the alterations affected carbohydrate,
lipid and amino acid metabolism, a similar profile to that
described in pre-malignant stages of MAT1A-/- liver.30 How-
ever, tumors showed a significant increase in enzymes involved
in purine and pyrimidine metabolism, according to the neces-
sity of proliferative cells to synthesize nucleic acids (Figure 3
of the Supporting Information). A group of 27 proteins changed
their levels in at least 50% of the MAT1A-/- inspected tumors
(Table 2) and, according to this criteria, were selected as
potential HCC-associated proteins. Among them, 19 were
down-regulated (Figure 4) whereas the other 8 were up-
regulated species, as deduced from 2-DE gel analysis (Figure
5). The up-regulated proteins were not detected in WT 2-DE
gels and gel spots of four of them (Serum albumin precursor,
42 kDa; protein disulfide isomerase, 42 kDa; aldehyde dehy-
drogenase mitochondrial, 36 kDa; glutathione S transferase
Mu1, 16 kDa) showed deviations from the expected pI or Mr
(Figure 5B), suggesting that the origin of these tumor-specific
species relates with postranslational events more likely than
involving changes of protein abundance as we previously
demonstrated in the case of Apo AI.47 Heat shock cognate 71
KDa protein is located in a zone with heavy streaking, therefore,
its up regulation has been further confirmed in MAT1A-/- liver
by Western blot analysis (data not shown). Interestingly, some
of these alterations were identified months before the develop-
ment of HCC in the liver of MAT1A-/- mice (Table 2). Down-
regulation of MAT, the knocked-out gene, selenium binding
protein and antioxidant protein 2 were already detected in liver
samples of 1 day old KO mice and, additionally, a decrease in
carbonic anhydrase III, sorbitol dehydrogenase, malate dehy-
drogenase, arginase 1, ornithine aminotransferase, Glycine-N-
methyltransferase, and alcohol dehydrogenase were assessed
in KO livers from 8 month old mice. Therefore, these proteins
might be considered as early markers of HCC in MAT1A-/-
mice.
Gene Expression Analysis in Human HCC. To investigate
whether the 27 proteins commonly altered in MAT1A-/- mice
were also associated with human HCC the expression levels of
the corresponding genes was measured by RT-PCR in tumors
from patients who developed HCC. Depletion of MAT1A and
GNMT genes in human hepatocarcinogenesis has been dem-
onstrated in previous studies.48 1300018L09 Rik and 280435D12
Rik proteins were not included initially in the analysis since
their biological function has not been clearly established to
date. The amount of transcripts was expressed as the relative
difference with respect to a control gene, histone H3F3A (2¢Ct,
were ¢Ct represents the differential number of cycles between
the target and the control gene).40 In all PCR experiments, the
expression level of these genes was measured in a cDNA pool
obtained from 5 transformed human cell lines (HepG2, Hep3B,
Huh7, PLC, and SKHep1) (not shown). The expression levels
of the 23 genes were always below 20% of those found in
control liver. RT-PCR analysis revealed down-regulation of 13
Table 2. Proteins Differentially Expressed in at Least 50% of MAT1A-/- Liver Tumorsa






Methionine adenosyltransferase Q91X83 43.5/5.8 8 25.7 Synthesis of AdoMet 6\6
Carbonic anhydrase III P16015 29.4/8.1 12 54.82 Reversible hydration of carbon dioxide 6\6
1300018L09 rik protein Q9DBB8 36.3/6.4 12 43.54 Catabolism of polycyclic aromatic hydrocarbons 5\6
Glutamine synthetase P15105 42.6/7.3 13 38.07 Nitrogen homeostasis 5\6
Selenium binding protein 2 Q63836 52.6/6.1 10 20.1 Bind selenium and acetaminophen 5\6
Adenosylhomocysteinase P50247 47.5/6.3 6 13.2 Regulation of adenosylhomocysteine levels 5\6
Antioxidant protein 2 O08709 24.7/5.9 7 40.35 Involved in redox regulation of the cell 5\6
Senescence marker protein 30 Q64374 33.4/5.2 10 44.81 Calcium homeostasis 5\6
Sorbitol dehydrogenase Q64442 40.1/7.0 20 52.26 Polyol pathway of glucose metabolism 3\6
Phenylalanine 4 hydroxylase P16331 51.9/6.3 13 25.38 Catabolism of phenylalanine 3\6
Malate dehydrogenase P14152 36.3/6.5 10 31.2 Involved in the tricarboxylic acid cycle 3\6
Arginase 1 Q61176 34.8/6.9 17 62.22 Arginine degradation via the urea cycle 3\6
Phosphoglucomutase Q9D0F9 61.3/6.6 23 47.41 Breakdown and synthesis of glucose 3\6
Ornithine aminotransferase P29758 48.3/6.5 12 33.03 Control de L-ornithine levels in tissues 3\6
Ornithine carbamoyltransferase P00481 39.7/9.0 5 17.51 Arginine biosynthesis 3\6
Non specific lipid transfer protein P32020 59.1/7.6 15 36.01 carrier for fatty acyl CoAs 3\6
Glycine N-methyltransferase Q91WN7 32.4/7.6 10 49.3 Methylation of glycine by using AdoMet 3\6
Alcohol dehydrogenase Q9JII6 36.4/7.3 17 63.88 Metabolism of ethanol 3\6
2810435D12 rik protein Q9CYW4 28.0/6.7 10 39.44 Hydrolase activity 3\6
Up-Regulated Proteins
Apolipoprotein A1 Q00623 30.5/5.8 11 40.5 Reverse transport of cholesterol to the liver 4\6
Apolipoprotein E P08226 35.8/5.6 16 44.7 binding and internalization of lipoproteins 4\6
Albumin P07724 68.7/6.0 10 16.11 Regulation of colloidal osmotic pressure of blood 4\6
Aldehyde dehydrogenase mit. P47738 56.5/8.0 12 27.16 Involved in ethanol utilization 3\6
Glutathione S-transferase Mu1 P10649 25.8/8.2 7 34.1 Detoxification of hydrophobic electrophiles 3\6
Glutathione S-transferase P2 P46425 23.4/8.1 6 41.62 Detoxification of hydrophobic electrophiles 3\6
Heat shock cognate 71KDa protein P63017 70.8/5.4 22 39.31 Stress-related, chaperone 3\6
Protein disulfide isomerase P09103 57.1/4.8 15 31.04 chaperone, isomerase and redox activities 3\6
a Proteins already altered in 1 day and 8 month old mice are indicated in italics and italics underlined, respectively.
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genes in human HCC samples: alcohol dehydrogenase, anti-
oxidant protein 2, senescence marker protein 30, nonspecific
lipid transfer protein, sorbitol dehydrogenase, albumin, phos-
phoglucomutase, phenylalanine 4 hydroxylase, apolipoprotein
A1, carbonic anhydrase III, aldehyde dehydrogenase class 2,
ornithine aminotransferase, and ornithine carbamoyltrans-
ferase (Figure 6). Two of them (aldehyde dehydrogenase and
apolipoprotein A1) vary in the opposite way as compared to
mice likely due to proteolytic cleavage (Figure 5B) and postra-
ductional modifications respectively.47 To determine whether,
in parallel with the results found in MAT1A-/- mice, these
alterations also occur in premalignant states, the expression
levels of the 13 positive genes was investigated in liver samples
from patients with alcoholic or viral cirrhosis who had not
developed HCC at the time of the study. The expression levels
of alcohol dehydrogenase, antioxidant protein 2, senescence
marker protein 30, nonspecific lipid transfer protein, sorbitol
dehydrogenase, albumin, and phosphoglucomutase, were sig-
nificantly reduced with respect to those measured in control
samples from healthy individuals (Figure 6). These changes
were also detected in peritumoral tissue samples from cirrhotic
patients. Cirrhotic patients displayed the same gene expression
profile independently on whether they had developed malig-
nant lesions or not and, consequently, were clustered into the
same group. Notably, although differences were not statistically
significant, the expression levels tended to be lower in samples
from patients with alcoholic cirrhosis than in patients with viral
cirrhosis and in the last group, higher levels were measured in
samples from patients who had not developed HCC. Finally,
the mRNA abundance of the 13 potential markers was mea-
sured in peritumoral samples from HCC patients who had not
developed liver fibrosis. In all cases, the only alteration statisti-
cally significant was the down-regulation of alcohol dehydro-
genase. Therefore, the cluster of 13 genes proposed here might
be of help in the prognosis of patients at risk to develop HCC.
Figure 5. 2-DE sections illustrating the up-regulated protein
species in at least 50% of MAT1A-/- tumors. Gel spots corre-
sponding to protein species with the expected Mr (A) or with Mr
values lower than those deduced from the amino acid sequence
(B) are shown. The Mr of reference proteins is indicated on the
left part of panel B.
Figure 4. 2-DE sections illustrating the down-regulated protein species in at least 50% of the analyzed MAT1A-/- tumors.
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Discussion
AdoMet has been generally considered as a central inter-
mediary metabolite involved in the synthesis of homocysteine
and polyamines as well as is the main cellular methyl group
donor.1 However, recent evidences indicate that in addition to
its central metabolic function, AdoMet is in the liver an
intracellular control switch that regulates essential hepatocyte’s
functions such as proliferation, differentiation and death.17
According to this, a deficiency of hepatic AdoMet synthesis has
been associated with the progression of liver diseases.48-52 To
better understand the mechanisms by which these nontradi-
tional functions of AdoMet take place, and the mechanisms
by which a chronic deficiency of this molecule in the liver
participates in the progression of HCC we have attempted a
comprehensive analysis of proteins associated with hepato-
carcinogenesis in MAT1A-/- mice using a combination of two-
dimensional electrophoresis (2-DE) and mass spectrometry to
then apply the resulting information to identify hallmarks of
HCC in humans.
Even though the main risk factors associated to the develop-
ment of HCC are known (hepatitis C and B viruses, aflatoxin
ingestion, abusive consumption of alcohol and genetic factors),
the traditional diagnostic methods are far from ensuring an
early detection of the disease and consequently the prognosis
of the patients at the time of diagnosis is poor.53 Different
genomic studies devoted to define the molecular pathogenesis
of HCC resulted in dissimilar profiles of up- and down-
regulated genes 41,54-56 These differences might result from the
distinct ethiology and differentiation state of the analyzed
tumors and suggest that diverse, and perhaps redundant,
mechanisms are involved in the control of cell proliferation
protecting cells from neoplastic transformation. This is com-
patible with the notion that the tumor may progress through
different pathways resulting in the molecular heterogeneity
denoted by genomic studies. According to this idea, the
proteomic profiles of different MAT1A-/- tumors showed higher
variability values than those found in controls or other pre-
neoplastic pathological conditions associated to this model. The
stochastic accumulation of errors in the biological program of
cellular systems during the development of tumors57 may
explain the 3-fold increase in the proteomic variability of
tumors excised from the same liver. However, proteomic
heterogeneity was increased up to 10-fold when lesions from
different mice were compared, suggesting that individual-
specific factors may impose a selective pressure on preneo-
plastic foci conditioning their evolution according to a
Darwinian selection system.57
Comparison of WT liver and MAT1A-/- tumor protein
profiles allowed the identification of 151 distinct peptidic
species that might be considered as a proteomic fingerprint of
HCC in this model and provide a molecular support to
representative alterations of dedifferentiated hepatocytes. In
agreement with previous studies describing changes in the
levels and physichochemical properties of protein species
concomitantly with the progression of HCC,41,54,56,58,59 deviations
from the expected Mr and pI according to the sequence of the
Figure 6. Expression levels of hallmark genes associated with human HCC. Down regulation of 13 genes in human HCC samples
(HCC) as compared with healthy individuals (C) was revealed by RT-PCR analysis. The expression levels of these genes was also
investigated in liver samples from patients with alcoholic (AC) or viral chirrosis (VC) and in peritumoral samples form HCC patients
who had not developed liver fibrosis (NC). Among them, 6 alterations were specific from HCC (specific), while the other 7 were common
to preneoplastic conditions such as cirrhosis (nonspecific). Statistical significance is indicated as follows: / p < 0.05, // p < 0.01, ///
p < 0.001.
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identified proteins have been detected. Most likely, these
abnormal species result from specific posttranslational modi-
fications, alternative splicing or atypical proteolytic events,58
as in the case of AOP2,60 GST61 and albumin.62 Most of the
alterations (61.3%) corresponded to down-regulated proteins
in tumor nodules, likely resulting from the progressive dedif-
ferentiation of hepatocytes during the transformation process.45
The functional clustering of all differential proteins indicates
an impaired metabolic activity as well as an increased response
to stress, and a deficient mitochondrial function in tumors. This
functional phenotype might represent the adaptation of hepa-
tocytes to the pressure imposed by the deficiency of AdoMet
in MAT1A-/- livers.28,29 Interestingly, these functional alterations
have been commonly reported in most proteomic and genomic
studies of HCC, including human samples. Since methionine
metabolism, including the AdoMet synthetic reaction, is se-
verely impaired in transformed hepatocytes,23-27 these alter-
ations might not be restricted to our experimental model but,
alternatively, they might represent, in general, the functional
profile of HCC. However, it is still obscure whether these
changes participate in the pathogenesis of HCC or if they are
only manifestations of the disease. Metabolic disturbances and
mitochondrial failure have been proposed as taking part in the
progression of various types of cancer.63,64 Additionally, these
alterations occur in MAT1A-/- liver months before any mani-
festation of liver disease could be detected by histological
examination,30 suggesting their participation in the develop-
ment of this HCC.
Differential proteomics has been recently applied to the
study of HCC resulting in panels of altered proteins that are
proposed as markers with central roles in the progression of
the disease in some cases.34,42-46,62,65-67 However, the protein
repertoires reported in these studies are barely coincident and,
consequently, their value as biomarkers of HCC is limited. The
discrepancies may arise from the experimental approach used
in each study, and from the specific biological properties of
the analyzed samples. This observation highlights the necessity
of establishing international rules for standarization at both
the analytical and diagnostic levels, to ensure obtaining of
comparable and reproducible results. Additionally, the use of
experimental models of hepatocarcinogenesis in which the
genetic background and the environmental conditions have
little impact on proteome variability, and that also facilitate
the design of longitudinal studies from preneoplastic stages,
may have a decisive impact in the identification of HCC
associated proteins.57 Among the 151 up- and down-regulated
proteins in MAT1A-/- tumors, 27 were differentially expressed
in at least 50% of the analyzed lesions and, based on this
observation, were considered as potential biomarkers of HCC.
Proteins previously associated with the progression of liver
disease in this model, such as ATPaseâ or PHB130 were not
considered for further investigations since they were found to
be up and down regulated respectively in only 30% of our
analysis. The selected proteins reproduce the functional phe-
notype of tumors, including metabolic enzymes and proteins
involved in detoxification and response to stress. Additionally,
selenium binding protein has been previously associated with
liver fibrosis68 and senescence69 supporting its association with
the development of tumors. Changes in sorbitol dehydrogenase
were previously used as indicative of liver damage.70,71 In
particular, the decrease of this activity in tumor nodules of
MAT1A-/- mice can be correlated with the reduced capacity
of transformed cells to metabolize sorbitol.72 Senescence
marker protein 30 is a calcium binding protein with a central
role in the preservation of liver homeostasis and cellular
function.73 Finally, glutamine synthase and ornithine amino-
transferase are metabolic enzymes involved in glutamine
metabolism. The overexpression of these enzymes, in part
through the Wnt/â-catenin pathway, has been related with liver
carcinogenesis.74,75 In rodents, it has been shown that a positive
glutamine synthase phenotype favored tumor growth but not
all lesions display this alteration.75 Down-regulation of glutamine
synthase in MAT1A-/- mice tumors might be a specific alter-
ation of this experimental model of chronic deficiency of
AdoMet in liver. Nevertheless, we cannot rule out the occur-
rence of posttranslational modifications resulting in a new
protein species that was not detected under the experimental
conditions of our analysis.
Different genomic and proteomic studies have used peritu-
moral tissue as a reference to detect changes on protein
expression associated with HCC.34,41,46,56,62,65 This approach
might conceal alterations common to peritumoral tissue and
tumors, hampering the detection of proteins which levels are
already modified in hepatitis or cirrhosis, conditions at risk of
HCC development.57 The use of MAT1A-/- mice as a filter
system previous to the analysis of human samples have
demonstrated its efficacy in the identification of hallmark
proteins of HCC. Proteome complexity was reduced to 27
potential biomarkers from which 15 have been validated in
human HCC samples by RT PCR analysis. Noteworthy, orni-
thine carbamoyltransferase, ornithine aminotransferase, car-
bonic anhydrase III, phosphoglucomutase and sorbitol dehy-
drogenase, were not associated with human HCC in previous
differential proteomic studies. Depletion of ornithine carbam-
oyltransferase, ornithine aminotransferase, aldehyde dehydro-
genase mitochondrial class 2, carbonic anhydrase III, apolipo-
protein A1, and phenylalanine 4 hydroxylase, were only observed
in tumors and, therefore, might be considered as indicative of
neoplastic transformation. However, the changes in alcohol
dehydrogenase, antioxidant protein 2, senescence marker
protein 30, nonspecific lipid transfer protein, sorbitol dehy-
drogenase, albumin, and phosphoglucomutase, together with
methionine adenosyltransferase and glycine-N-methyltrans-
ferase48 were detected in cirrhotic liver independently on
whether the analyzed tissue were associated to a tumor or not.
Since cirrhosis is considered at high risk for HCC development,
these alterations might be considered as early markers that may
contribute to the molecular definition of preneoplastic states.
Interestingly, the levels of these proteins in nonfibrotic peri-
tumoral tissue were found to be similar to those found in
control individuals with the only exception of alcohol dehy-
drogenase that has been previously associated with liver
diseases of diverse ethiology.76 Finally, although results were
not statistically significant, Hsp71 cognate was increased in 40%
of the analyzed tumors, a similar proportion to that found
previously,77 and the results obtained for glutamine synthase
are compatible with studies showing that only certain HCC
human tumors are positive for this protein,78-80 although
glutamine is essential to promote tumor growth.81
In summary, we have investigated in the present work the
molecular mechanisms associated with the progression of HCC
under a chronic deficiency of AdoMet in the liver. Proteomic
analysis of MAT1A-/- tumors revealed the existence of individual-
specific factors that might condition the development of
preneoplastic lesions. Additionally, of the 27 proteins differ-
entially expressed in at least 50% of the analyzed tumors, 15
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were confirmed in human samples and some of them were
already altered in preneoplastic alterations. Among them, 15
were validated as markers of human HCC, and 7 were shown
to be altered in premalignant pathological conditions. Our
results in combination with other classical diagnostic methods,
might help to the early detection of HCC.
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